Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811160 | PMC |
| http://dx.doi.org/10.1172/JCI87345 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MicroRNA-146b: A Novel Biomarker and Therapeutic Target for Human Papillary Thyroid Cancer.
Int J Mol Sci
March 2017
Graduate Institute of Clinical Medical Sciences, Chang Gung University, Kaohsiung City 833, Taiwan.
Papillary thyroid cancer (PTC) is the most common tumor subtype of thyroid cancer. However, not all PTCs are responsive to current surgical and radioiodine treatment. The well-established clinical prognostic factors include tumor size, lymph node/distal metastasis, and extrathyroidal invasion.
View Article and Find Full Text PDFThe RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.
J Clin Invest
April 2005
Istituto di Endocrinologia ed Oncologia Sperimentale del CNR G. Salvatore, Dipartimento di Biologia e Patologia Cellulare e Molecolare, University Federico II, Naples, Italy.
In papillary thyroid carcinomas (PTCs), rearrangements of the RET receptor (RET/PTC) and activating mutations in the BRAF or RAS oncogenes are mutually exclusive. Here we show that the 3 proteins function along a linear oncogenic signaling cascade in which RET/PTC induces RAS-dependent BRAF activation and RAS- and BRAF-dependent ERK activation. Adoptive activation of the RET/PTC-RAS-BRAF axis induced cell proliferation and Matrigel invasion of thyroid follicular cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!